October 9, 2025
Publications & Posters
Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2
October 9, 2025
Press Release
Vividion Announces Publication in Science of Preclinical Data on Covalent Inhibitors of RAS-PI3K that Block Tumor Growth
August 13, 2025
Press Release
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer
June 4, 2025
Press Release
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor
April 3, 2025
Press Release
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors